Sonrai partners with US biotech to advance ovarian cancer detection

Sonrai partners with US biotech to advance ovarian cancer detection

AOA Dx will be supported by Sonrai Analytics to accelerate the development of its ovarian cancer detection test.

Ovarian cancer is one of the most difficult types of gynecological cancer to diagnose in early stages, and that makes it a silent threat to women's health.Its development can progress without obvious signs and, when symptoms finally appear, they are often confused with common digestive or urinary tract discomfort.What is the first symptom of ovarian cancer?One of the first signs that usually appears - and many women ignore - is persistent abdomi…

Sonrai and AOA Dx partner to accelerate ovarian cancer test development

Strategic collaboration aims to improve early diagnosis

Northway Biotech Signs Deal with Kaida BioPharma for Production of Kaida's Ovarian Cancer Therapeutic

Officials at Northway Biotech say they will leverage the company’s expertise to develop a robust manufacturing process for KAD101. This involves Northway’s developing and qualifying analytical methods, optimizing the formulation, development and scaling up of the production process, and manufacturing a cGMP drug substance batch for clinical studies. “We are incredibly pleased to establish this important partnership with Northway Biotech, a pre-e…